Yaghjyan Lusine, Wijayabahu Akemi, Eliassen A Heather, Colditz Graham, Rosner Bernard, Tamimi Rulla M
Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, 2004 Mowry Rd, Gainesville, FL, 32610, USA.
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Cancer Causes Control. 2020 Sep;31(9):827-837. doi: 10.1007/s10552-020-01321-0. Epub 2020 May 31.
We investigated the associations of aspirin and other non-steroid anti-inflammatory drugs with mammographic breast density (MBD) and their interactions in relation to breast cancer risk.
This study included 3,675 cancer-free women within the Nurses' Health Study (NHS) and Nurses' Health Study II (NHSII) cohorts. Percent breast density (PD), absolute dense area (DA), and non-dense area (NDA) were measured from digitized film mammograms using a computer-assisted thresholding technique; all measures were square root-transformed. Information on medication use was collected in 1980 (NHS) and 1989 (NHSII) and updated biennially. Medication use was defined as none, past or current; average cumulative dose and frequency were calculated for all past or current users from all bi-annual questionnaires preceding the mammogram date. We used generalized linear regression to quantify associations of medications with MBD. Two-way interactions were examined in logistic regression models.
In multivariate analysis, none of the anti-inflammatory medications were associated with PD, DA, and NDA. We found no interactions of any of the medications with PD with respect to breast cancer risk (all p-interactions > 0.05). However, some of the aspirin variables appeared to have positive associations with breast cancer risk limited only to women with PD 10-24% (past aspirin OR 1.56, 95% CI 1.03-2.35; current aspirin with < 5 years of use OR 1.82, 95% CI 1.01-3.28; current aspirin with ≥ 5 years of use OR 1.89, 95% CI 1.26-2.82).
Aspirin and NSAIDs are not associated with breast density measures. We found no interactions of aspirin with MBD in relation to breast cancer risk.
我们研究了阿司匹林和其他非甾体抗炎药与乳腺钼靶密度（MBD）的关联及其与乳腺癌风险的相互作用。
本研究纳入了护士健康研究（NHS）和护士健康研究II（NHSII）队列中的3675名无癌女性。使用计算机辅助阈值技术从数字化乳腺钼靶片中测量乳腺密度百分比（PD）、绝对致密面积（DA）和非致密面积（NDA）；所有测量值均进行平方根转换。1980年（NHS）和1989年（NHSII）收集了用药信息，并每两年更新一次。用药情况定义为无、过去或现在使用；根据乳腺钼靶检查日期之前所有两年期问卷，计算所有过去或现在使用者的平均累积剂量和使用频率。我们使用广义线性回归来量化药物与MBD的关联。在逻辑回归模型中检验双向相互作用。
在多变量分析中，没有一种抗炎药物与PD、DA和NDA相关。我们发现任何一种药物与PD在乳腺癌风险方面均无相互作用（所有p相互作用>0.05）。然而，一些阿司匹林变量似乎仅与PD为10 - 24%的女性的乳腺癌风险呈正相关（过去使用阿司匹林的比值比[OR]为1.56，95%置信区间[CI]为1.03 - 2.35；使用年限<5年的当前使用阿司匹林的OR为1.82，95% CI为1.01 - 3.28；使用年限≥5年的当前使用阿司匹林的OR为1.89，95% CI为1.26 - 2.82）。
阿司匹林和非甾体抗炎药与乳腺密度测量值无关。我们发现阿司匹林与MBD在乳腺癌风险方面无相互作用。
